These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 17342635)

  • 21. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.
    Nauck MA; Duran S; Kim D; Johns D; Northrup J; Festa A; Brodows R; Trautmann M
    Diabetologia; 2007 Feb; 50(2):259-67. PubMed ID: 17160407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exenatide: from the Gila monster to the pharmacy.
    Triplitt C; Chiquette E
    J Am Pharm Assoc (2003); 2006; 46(1):44-52; quiz 53-5. PubMed ID: 16529340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exenatide.
    Bray GM
    Am J Health Syst Pharm; 2006 Mar; 63(5):411-8. PubMed ID: 16484515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exenatide.
    Barnett AH
    Drugs Today (Barc); 2005 Sep; 41(9):563-78. PubMed ID: 16341288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exenatide: new drug. Type 2 diabetes for some overweight patients.
    Prescrire Int; 2007 Dec; 16(92):228-31. PubMed ID: 18087791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.
    McCormack PL
    Drugs; 2014 Mar; 74(3):325-51. PubMed ID: 24435322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exenatide: its position in the treatment of type 2 diabetes.
    Guerci B; Martin CS
    Ann Endocrinol (Paris); 2008 Jun; 69(3):201-9. PubMed ID: 18533126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
    Gallwitz B
    Drugs; 2011 Sep; 71(13):1675-88. PubMed ID: 21902291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
    Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
    Nielsen LL; Young AA; Parkes DG
    Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New drugs; exenatide and sitagliptin].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Apr; 152(15):876-9. PubMed ID: 18512528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.
    Madsbad S
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):463-77. PubMed ID: 19748064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?
    Nauck MA; Meier JJ
    Nat Rev Endocrinol; 2011 Apr; 7(4):193-5. PubMed ID: 21326278
    [No Abstract]   [Full Text] [Related]  

  • 38. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.
    Painter NA; Morello CM; Singh RF; McBane SE
    J Am Board Fam Med; 2013; 26(2):203-10. PubMed ID: 23471935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
    Hansen KB; Knop FK; Holst JJ; Vilsbøll T
    Int J Clin Pract; 2009 Aug; 63(8):1154-60. PubMed ID: 19624785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is exenatide advancing the treatment of type 2 diabetes?
    Doggrell SA
    Expert Opin Pharmacother; 2006 Jan; 7(1):109-12. PubMed ID: 16370928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.